In this study, we sought to examine vascular ephrinB2 from a metastatic angle and incorporated RT due to the ability of RT to enhance anti-tumor immunity (Bickett et al., 2021; Darragh et al., 2022; M. W. Knitz et al., 2021; Oweida et al., 2018; Oweida et al., 2017; Oweida, Darragh, et al., 2019) and its use as a standard-of-care therapy for HNSCC patients (Pfister et al., 2020; Xing et al., 2021). This evidence concerns the gene EFNB2 and neoplasm.